Amanta Healthcare Announces IPO Launch: 1 Crore Fresh Shares on Offer
Amanta Healthcare, a pharmaceutical company, is launching its IPO from September 1-3, offering 1 crore equity shares. The IPO allocation includes 50% for QIBs, 35% for retail investors, and 15% for NIIs. The company plans to list on BSE and NSE on September 8. Amanta Healthcare reported revenue of ₹276.09 crore and profit after tax of ₹10.50 crore in FY25. The IPO proceeds will fund new manufacturing lines and corporate purposes.
*this image is generated using AI for illustrative purposes only.
Amanta Healthcare, a pharmaceutical company specializing in sterile liquid formulations and medical devices, has announced the launch of its Initial Public Offering (IPO) scheduled for September 1. The company plans to offer 1 crore equity shares through a fresh issue, with the subscription window open until September 3.
IPO Details
- Subscription Period: September 1 - September 3
- Expected Allotment Date: September 4
- Planned Listing Date: September 8
- Listing Venues: BSE and NSE
- Total Shares on Offer: 1 crore (fresh issue)
The price band for the IPO has not been announced yet.
Allocation Structure
The issue has been structured with the following allocation:
- Up to 50% reserved for Qualified Institutional Buyers (QIBs)
- At least 35% allocated for retail investors
- A minimum of 15% set aside for Non-Institutional Investors (NIIs)
Company Overview
Amanta Healthcare, incorporated in 1994, has established itself as a developer and manufacturer of sterile liquid formulations and medical devices. The company boasts a portfolio of over 45 generic products, which are distributed through a network of 320 distributors across India. Additionally, Amanta Healthcare has expanded its reach to 21 countries through exports.
Financial Performance
The company's recent financial performance shows mixed results:
| Fiscal Year | Revenue (₹ Crore) | Profit After Tax (₹ Crore) |
|---|---|---|
| FY25 | 276.09 | 10.50 |
| FY24 | 281.61 | 3.63 |
While revenue saw a slight decrease from ₹281.61 crore in FY24 to ₹276.09 crore in FY25, the company's profit after tax witnessed a substantial increase, rising from ₹3.63 crore to ₹10.50 crore.
Use of IPO Proceeds
Amanta Healthcare has outlined the following plans for utilizing the funds raised through the IPO:
- ₹70.00 crore for establishing a new SteriPort manufacturing line
- ₹30.13 crore for setting up an SVP line at Hariyala
- The remaining funds will be allocated for general corporate purposes
Investors and market observers will be closely watching this IPO, given the company's established presence in the pharmaceutical sector and its recent profit growth. As the launch date approaches, more details, including the price band, are expected to be announced.
16
